www.feizichem.com    Shijiazhuang FeiZi Chemical Technology Co., Ltd.

As global demand for psychotropic medications continues to grow, the stable supply of key intermediates upstream in the antipsychotic drug industry chain has come under increasing scrutiny. Shijiazhuang Feizi Chemical Technology Co., Ltd. (hereinafter referred to as "Feizi Chemical"), leveraging its mature synthesis processes and stringent quality control system, has achieved large-scale, stable supply of its core product—10,11-Dihydro-11-oxodibenzo[b,f][1,4]thiazepine ( DBTO, CAS No.: 3159-07-7), which is now widely exported to markets both domestically and internationally.

Product positioning: A key intermediate in the synthesis of quetiapine.

DBTO is a key intermediate in the synthesis of the atypical antipsychotic drug quetiapine fumarate. As a representative of second-generation antipsychotics, quetiapine is widely used in the treatment of mental disorders such as schizophrenia and bipolar disorder, and global market demand remains robust.

The three-ring structure of DBTO—a two-benzene-ring system fused to a seven-membered sulfur-nitrogen heterocyclic ring—is the core molecular building block for constructing the pharmacophore of quetiapine. The purity and quality of this intermediate directly affect the yield of the downstream active pharmaceutical ingredient and the final quality of the drug product; therefore, it places high demands on the manufacturing companies’ process expertise and quality-control capabilities.

Feizi Chemical: Mature technology, controllable quality. Feizi Chemical has the following core advantages in DBTO products:

·High Purity: The product purity can reach over 99%, meeting the standards for pharmaceutical-grade intermediates. ·Stable process: Good batch consistency and stable yield;

Strict quality control: A comprehensive testing system covering multiple indicators has been established, from raw material entry into the factory to finished product dispatch. Reliable supply: Possesses continuous supply capabilities to meet bulk procurement needs of pharmaceutical companies both domestically and internationally. Currently, Feizi Chemical’s DBTO product has been launched and is being showcased on several mainstream chemical platforms, and its market acceptance continues to rise. Market Outlook: Expansion of Psychiatric Drug Market Drives Demand for Intermediates

According to industry analysis, as the global prevalence of mental disorders rises and treatment rates among patients increase, the antipsychotic drug market is maintaining a steady growth trend. Quetiapine, as one of the fundamental drugs in this field, continues to drive demand for its generic drugs and active pharmaceutical ingredients, which in turn sustains the need for upstream intermediates. As a key intermediate in the quetiapine synthesis pathway, DBTO exhibits highly rigid market demand.

Feizi Chemical stated that the company will continue to optimize the production processes for DBTO and related pharmaceutical intermediates, enhance product quality and supply capacity, and provide globally competitive intermediate solutions for pharmaceutical customers.

About Shijiazhuang Feizi Chemical Technology Co., Ltd.

Shijiazhuang Feizi Chemical Technology Co., Ltd. is a technology-driven enterprise specializing in the R&D, production, and sales of fine chemicals and pharmaceutical intermediates. Its product portfolio covers multiple series, including sulfonate salts, pyrimidine derivatives, piperazine derivatives, and naphthalene-based compounds, which are widely used in fields such as pharmaceuticals, dyes, and daily chemical products. Adhering to the business philosophy of "quality first, customer paramount," the company is committed to providing global customers with high-quality chemical products and professional services.